Correction to: efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
BMC Pharmacology and Toxicology volume 24, Article number: 49 (2023)
Correction to: BMC Pharmacol Toxicol 19, 63 (2018).
The original publication of this article did not provide clear clarification that the switch from brand to a generic drug was not done by the authors for the intention of the study. Patients were informed of the options and on switching to generic drugs the patients were able to expressed their agreements or disagreements, those who expressed their disagreement continued with their regimen.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s40360-018-0252-z.
About this article
Cite this article
Olalla, J., Pérez-Stachowski, J., Tortajada, B. et al. Correction to: efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks. BMC Pharmacol Toxicol 24, 49 (2023). https://doi.org/10.1186/s40360-023-00693-8